Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Rank in Stocks #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Share Price
$15.31
Last synced: 2024-02-29
Market Cap
$45.70M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Icosavax, Inc. (ICVX)

Category

Stock split history for Icosavax, Inc. (ICVX)
Icosavax, Inc. stock (symbol: ICVX) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 20, 2026.
One ICVX share bought prior to Aug 20, 2026 would equal to 0 ICVX shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
1 x3
AU
0 -
CH
0 -
US